Evaluation of loxapine succinate in chronic schizophrenia.
D000328:Adult; D000704:Analysis of Variance; D001480:Basal Ganglia Diseases / Q000139:chemically induced; D001835:Body Weight / Q000187:drug effects; D002746:Chlorpromazine / Q000008:administration & dosage / Q000627:therapeutic use; D002784:Cholesterol / Q000097:blood; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D003989:Dibenzoxazepines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000188:drug therapy*; D013610:Tachycardia / Q000139:chemically induced; D014149:Tranquilizing Agents / Q000627:therapeutic use*
D003989:Dibenzoxazepines; D010919:Placebos; D014149:Tranquilizing Agents; D002784:Cholesterol; D002746:Chlorpromazine